Journal article · 2021 · Open access

Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance

Leah F. Moriarty, Papy Mandoko Nkoli, Joris Losimba Likwela, Patrick Mitashi, Éric Mukomena Sompwe, Junior Rika Matangila, Hypolite Muhindo Mavoko, Samaly S. Svigel, Sam P. Jones, Nsengi Y. Ntamabyaliro, Albert Kutekemeni, Naomi W. Lucchi and 10 more

American Journal of Tropical Medicine and Hygiene, 105(4), 1067–1075 · Published 7 September 2021 · DOI 10.4269/ajtmh.21-0214

Open PDFView at the publisherCite this paper

In brief

“Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance” is a 2021 journal article by Leah F. Moriarty and 21 co-authors, published in American Journal of Tropical Medicine and Hygiene. OpenAlex counts 64 citations as of 19 November 2026. It is open access: the full text is free to read at American Journal of Tropical Medicine and Hygiene.

Citations
64
Most cited in
2026 (18)
Field-weighted impact
5.92
References
23
Authors
22

Abstract

Routine assessment of the efficacy of artemisinin-based combination therapies (ACTs) is critical for the early detection of antimalarial resistance. We evaluated the efficacy of ACTs recommended for treatment of uncomplicated malaria in five sites in Democratic Republic of the Congo (DRC): artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP). Children aged 6-59 months with confirmed Plasmodium falciparum malaria were treated with one of the three ACTs and monitored. The primary endpoints were uncorrected and polymerase chain reaction (PCR)-corrected 28-day (AL and ASAQ) or 42-day (DP) cumulative efficacy. Molecular markers of resistance were investigated. Across the sites, uncorrected efficacy estimates ranged from 63% to 88% for AL, 73% to 100% for ASAQ, and 56% to 91% for DP. PCR-corrected efficacy estimates ranged from 86% to 98% for AL, 91% to 100% for ASAQ, and 84% to 100% for DP. No pfk13 mutations previously found to be associated with ACT resistance were observed. Statistically significant associations were found between certain pfmdr1 and pfcrt genotypes and treatment outcome. There is evidence of efficacy below the 90% cutoff recommended by WHO to consider a change in first-line treatment recommendations of two ACTs in one site not far from a monitoring site in Angola that has shown similar reduced efficacy for AL. Confirmation of these findings in future therapeutic efficacy monitoring in DRC is warranted.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Moriarty, L. F., Nkoli, P. M., Likwela, J. L., Mitashi, P., Sompwe, É. M., Matangila, J. R., Mavoko, H. M., Svigel, S. S., Jones, S. P., Ntamabyaliro, N. Y., Kutekemeni, A., Lucchi, N. W., Subramaniam, G., Niang, M., Sadou, A., Ngoyi, D. M., Tamfum, J. J. M., Schmedes, S. E., Pluciński, M. M., . . . Kahunu, G. M. (2021). Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance. American Journal of Tropical Medicine and Hygiene, 105(4), 1067–1075. https://doi.org/10.4269/ajtmh.21-0214

MLA 9

Moriarty, Leah F., et al. “Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance.” American Journal of Tropical Medicine and Hygiene, vol. 105, no. 4, 2021, pp. 1067–1075. https://doi.org/10.4269/ajtmh.21-0214.

Chicago

Moriarty, Leah F., Papy Mandoko Nkoli, Joris Losimba Likwela, Patrick Mitashi, Éric Mukomena Sompwe, Junior Rika Matangila, Hypolite Muhindo Mavoko, et al. 2021. “Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance.” American Journal of Tropical Medicine and Hygiene 105 (4): 1067–1075. https://doi.org/10.4269/ajtmh.21-0214.

Harvard

Moriarty, L. F. et al. (2021) ‘Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance’, American Journal of Tropical Medicine and Hygiene, 105(4), pp. 1067–1075. doi:10.4269/ajtmh.21-0214.

IEEE

L. F. Moriarty et al., “Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance,” American Journal of Tropical Medicine and Hygiene, vol. 105, no. 4, pp. 1067–1075, 2021, doi: 10.4269/ajtmh.21-0214.

BibTeX

@article{moriarty2021therapeutic,
  title     = {{Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance}},
  author    = {Moriarty, Leah F. and Nkoli, Papy Mandoko and Likwela, Joris Losimba and Mitashi, Patrick and Sompwe, Éric Mukomena and Matangila, Junior Rika and Mavoko, Hypolite Muhindo and Svigel, Samaly S. and Jones, Sam P. and Ntamabyaliro, Nsengi Y. and Kutekemeni, Albert and Lucchi, Naomi W. and Subramaniam, Gireesh and Niang, Mame and Sadou, Aboubacar and Ngoyi, Dieudonné Mumba and Tamfum, Jean Jacques Muyembe and Schmedes, Sarah E. and Pluciński, Mateusz M. and Chowell, Gerardo and Halsey, Eric S. and Kahunu, Gauthier Mesia},
  journal   = {American Journal of Tropical Medicine and Hygiene},
  year      = {2021},
  volume    = {105},
  number    = {4},
  pages     = {1067--1075},
  doi       = {10.4269/ajtmh.21-0214},
  url       = {https://doi.org/10.4269/ajtmh.21-0214}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202111
202244
20231515
20241414
20251212
20261818

Its field-weighted citation impact is 5.92: it has been cited 5.92 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control

  • artemisinin-based combination therapy
  • antimalarial drug resistance
  • falciparum malaria
  • treatment efficacy
  • artemether-lumefantrine
  • artesunate-amodiaquine
  • dihydroartemisinin-piperaquine
  • pfk13 mutations

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Moriarty, L. F., Nkoli, P. M., Likwela, J. L., Mitashi, P., Sompwe, É. M., Matangila, J. R., Mavoko, H. M., Svigel, S. S., Jones, S. P., Ntamabyaliro, N. Y., Kutekemeni, A., Lucchi, N. W., Subramaniam, G., Niang, M., Sadou, A., Ngoyi, D. M., Tamfum, J. J. M., Schmedes, S. E., Pluciński, M. M., . . . Kahunu, G. M. (2021). Therapeutic Efficacy of Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation of Molecular Markers of Antimalarial Resistance. American Journal of Tropical Medicine and Hygiene, 105(4), 1067–1075. https://doi.org/10.4269/ajtmh.21-0214

How many times has this paper been cited?

64 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at American Journal of Tropical Medicine and Hygiene: sign in and open the PDF from this page.

Who wrote this paper?

Leah F. Moriarty, Papy Mandoko Nkoli, Joris Losimba Likwela, Patrick Mitashi, Éric Mukomena Sompwe, Junior Rika Matangila, Hypolite Muhindo Mavoko, Samaly S. Svigel, Sam P. Jones, Nsengi Y. Ntamabyaliro, Albert Kutekemeni, Naomi W. Lucchi and 10 more.

What is the DOI of this paper?

10.4269/ajtmh.21-0214, permanently at https://doi.org/10.4269/ajtmh.21-0214. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.